RYTHM (RYM) & Its Peers Critical Survey

RYTHM (NASDAQ:RYM) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare RYTHM to similar companies based on the strength of its valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Insider & Institutional Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares RYTHM and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,299.79%	-222.94%	-17.42%

Valuation and Earnings

This table compares RYTHM and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$51.01 million	-$33.26 million	-2.22
RYTHM Competitors	$5.19 billion	$3.13 billion	543.59

RYTHM’s rivals have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

RYTHM has a beta of 9.44, suggesting that its share price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s rivals have a beta of -3.19, suggesting that their average share price is 419% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for RYTHM and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7588	13653	25447	996	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 32.22%. Given RYTHM’s rivals stronger consensus rating and higher probable upside, analysts plainly believe RYTHM has less favorable growth aspects than its rivals.

Summary

RYTHM rivals beat RYTHM on 9 of the 13 factors compared.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.